Lista de obras - A Tiede - Dominio Público Uruguay

A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.

artículo científico publicado en 2014

Acquired bleeding disorders

artículo científico publicado en 2020

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

artículo científico publicado en 2014

Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study.

artículo científico publicado en 2016

Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations

artículo científico publicado en 2008

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.

artículo científico publicado en 2011

Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes.

artículo científico publicado en 1999

Bleeding symptoms in patients diagnosed as type 3 Von Willebrand Disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study

scientific article published on 07 May 2020

CD8alpha+beta(low) effector T cells in systemic lupus erythematosus

artículo científico publicado en 2008

Characterisation of the enzymatic complex for the first step in glycosylphosphatidylinositol biosynthesis.

artículo científico publicado en 2000

Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement

scientific article published on 13 September 2019

Co-morbidities and bleeding in elderly patients with haemophilia-A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH).

artículo científico publicado en 2017

Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure

artículo científico publicado en 2021

Compensatory visual field training for patients with hemianopia after stroke

artículo científico publicado en 2001

Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia

article

Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study

scientific article published on 12 September 2019

Current Diagnostic and Therapeutic Approaches to Patients with Acquired von Willebrand Syndrome: A 2013 Update ⬇️

artículo científico publicado el 8 de febrero de 2013

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders

artículo científico

DNA analysis from stool samples: a fast and reliable method avoiding invasive sampling methods in mouse models of bleeding disorders.

artículo científico publicado en 2009

Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro.

artículo científico publicado en 2015

Diagnosis and treatment of acquired von Willebrand syndrome.

artículo científico publicado en 2012

Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study

artículo científico publicado en 2008

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.

artículo científico publicado en 2012

Effect of TNF-alpha blockade on coagulopathy and endothelial cell activation in xenoperfused porcine kidneys

artículo científico publicado en 2015

Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys

scientific article published on 01 February 2008

Effects of platelet concentrate storage time reduction in patients after blood stem cell transplantation ⬇️

artículo científico publicado el 22 de marzo de 2013

Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.

artículo científico publicado en 2013

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model

artículo científico publicado en 2020

Half-life extended factor VIII for the treatment of hemophilia A.

artículo científico

How I treat the acquired von Willebrand syndrome ⬇️

artículo científico publicado el 3 de mayo de 2011

Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia.

artículo científico publicado en 2004

Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland

artículo científico publicado en 2008

Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin

artículo científico publicado en 2012

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A

artículo científico publicado en 2021

Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulation

artículo científico publicado en 2016

Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges

artículo científico publicado en 2014

Legionnaires' disease in immunocompromised patients: a case report of Legionella longbeachae pneumonia and review of the literature

artículo científico publicado en 2008

Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia

article

Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial

artículo científico publicado en 2018

On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.

artículo científico publicado en 2011

PK-guided personalized prophylaxis with Nuwiq(®) (human-cl rhFVIII) in adults with severe haemophilia A.

artículo científico publicado en 2017

Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats

artículo científico

Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice

artículo científico publicado en 2013

Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B

scientific article published on 08 April 2020

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

artículo científico publicado en 2017

Pigs transgenic for human thrombomodulin have elevated production of activated protein C

scientific article published on 01 November 2009

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.

artículo científico publicado en 2014

Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and O

article

Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.

artículo científico publicado en 2015

Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary

artículo científico publicado en 2020

Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.

artículo científico publicado en 2003

Recombinant human antithrombin prevents xenogenic activation of hemostasis in a model of pig-to-human kidney transplantation

artículo científico publicado en 2014

Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study

artículo científico publicado en 2020

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.

artículo científico publicado en 2013

SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

artículo científico publicado en 2019

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

artículo científico publicado en 2012

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).

artículo científico publicado en 2011

Should Emicizumab Be Used in Patients with Acquired Hemophilia A?

artículo científico publicado en 2020

Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.

artículo científico publicado en 2015

The first recombinant FVIII produced in human cells--an update on its clinical development programme.

artículo científico

The rising incidence of acquired haemophilia A in Germany

scientific article published on 16 September 2020

The use of recombinant activated factor VII in patients with acquired haemophilia

artículo científico

Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia.

artículo científico publicado en 2008

Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys

artículo científico publicado en 2011

Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).

artículo científico publicado en 2007

[Perioperative hemostasis management]

artículo científico publicado en 2007

[Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients]

scientific article published on 01 January 2014

[Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis]

artículo científico publicado en 2012

siRNA mediated knockdown of tissue factor expression in pigs for xenotransplantation.

artículo científico publicado en 2015

Lista de obras de A Tiede

A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.

Acquired bleeding disorders

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans

Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study.

Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.

Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes.

Bleeding symptoms in patients diagnosed as type 3 Von Willebrand Disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study

CD8alpha+beta(low) effector T cells in systemic lupus erythematosus

Characterisation of the enzymatic complex for the first step in glycosylphosphatidylinositol biosynthesis.

Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement

Co-morbidities and bleeding in elderly patients with haemophilia-A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH).

Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure

Compensatory visual field training for patients with hemianopia after stroke

Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia

Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study

Current Diagnostic and Therapeutic Approaches to Patients with Acquired von Willebrand Syndrome: A 2013 Update ⬇️

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders

DNA analysis from stool samples: a fast and reliable method avoiding invasive sampling methods in mouse models of bleeding disorders.

Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro.

Diagnosis and treatment of acquired von Willebrand syndrome.

Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.

Effect of TNF-alpha blockade on coagulopathy and endothelial cell activation in xenoperfused porcine kidneys

Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys

Effects of platelet concentrate storage time reduction in patients after blood stem cell transplantation ⬇️

Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model

Half-life extended factor VIII for the treatment of hemophilia A.

How I treat the acquired von Willebrand syndrome ⬇️

Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia.

Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland

Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A

Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulation

Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges

Legionnaires' disease in immunocompromised patients: a case report of Legionella longbeachae pneumonia and review of the literature

Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia

Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial

On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.

PK-guided personalized prophylaxis with Nuwiq(®) (human-cl rhFVIII) in adults with severe haemophilia A.

Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats

Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice

Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

Pigs transgenic for human thrombomodulin have elevated production of activated protein C

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.

Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and O

Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.

Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary

Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.

Recombinant human antithrombin prevents xenogenic activation of hemostasis in a model of pig-to-human kidney transplantation

Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.

SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).

Should Emicizumab Be Used in Patients with Acquired Hemophilia A?

Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.

The first recombinant FVIII produced in human cells--an update on its clinical development programme.

The rising incidence of acquired haemophilia A in Germany

The use of recombinant activated factor VII in patients with acquired haemophilia

Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia.

Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys

Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).

[Perioperative hemostasis management]

[Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients]

[Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis]

siRNA mediated knockdown of tissue factor expression in pigs for xenotransplantation.